Reports Q4 R&D expenses totaled $44.6M for the quarter, a decrease driven primarily by lower early-stage R&D activities, and the company reported ending the year with $756.5M in cash, cash equivalents, and marketable securities. “This year is a pivotal period for Spyre as we begin to unveil results from our two groundbreaking Phase 2 trials with the potential to identify multiple products that leapfrog today’s standard of care and provide substantially improved therapies for patients suffering from severe autoimmune diseases,” said CEO Cameron Turtle.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics files automatic mixed securities shelf
- Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
- Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
- Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
- Spyre Therapeutics falls -7.4%